- Trial phase
- Phase 3
- Time to market
- At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
- Why 6/10
- The next hard, dated catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. This is ~2 weeks away, and gotistobart is a significant but not the sole late-stage asset in BioNTech's broad pipeline, warranting a 6.
The key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.
Price Chart
Executive Summary
Gotistobart is an oncology immunotherapy drug from BioNTech SE (BNTX, Nasdaq), being evaluated in a Phase 3 trial (PRESERVE-003) for squamous non-small cell lung cancer and a Phase 2 trial (PRESERVE-004) for platinum-resistant ovarian cancer. At the European Lung Cancer Congress 2026, gotistobart demonstrated a 54% reduction in risk of death in squamous NSCLC. The next major catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial will be presented. BioNTech has a broad late-stage oncology pipeline with 25+ Phase 2/3 trials, and analyst consensus is strongly bullish (22 buy/strong buy ratings, mean price target $121). However, the company is still pre-commercial in oncology, posting net losses as COVID vaccine revenue declines.
How It Works
Gotistobart is an oncology immunotherapy agent being developed by BioNTech. While its exact molecular target is not fully detailed in public disclosures, it is designed to stimulate the immune system to attack cancer cells. It is being studied in non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer.
Trial Status
Gotistobart is being evaluated in the Phase 3 PRESERVE-003 trial for squamous non-small cell lung cancer (updated OS data to be presented at WCLC Sept 12-15, 2026) and the Phase 2 PRESERVE-004 trial for platinum-resistant ovarian cancer (data presented at ASCO 2026). At ELCC 2026, gotistobart showed a 54% reduction in risk of death in squamous NSCLC.
The Two-Sided Case
Upcoming Catalysts
- WCLC 2026 (Sept 12-15, 2026): Updated overall survival data from Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BioNTech SE 6-K BNTX ·Originating report